GlassScriptPhysician profile
Ramanath Bhandari
NPI 1255594248
$111,516.61
in general payments reported to CMS, 2019-2025
16 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $6,298 · 2021: $11K · 2022: $5,651 · 2023: $14K · 2024: $39K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $13K · Food and Beverage: $3,744 · Consulting Fee: $2,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,863.66 |
| Travel and Lodging | $13,177.14 |
| Food and Beverage | $3,743.62 |
| Consulting Fee | $2,887.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $96,137.18 | 2020-2025 | Eylea Hd, Eylea |
| Regeneron Pharmaceuticals, INC. | $3,958.06 | 2021-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $3,338.36 | 2023-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $2,891.80 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $2,600.37 | 2022-2024 | Syfovre |
| Genentech USA, INC. | $627.51 | 2020-2025 | Vabysmo |
| Astellas Pharma US INC | $619.29 | 2023-2025 | Izervay |
| Ocular Therapeutix, INC. | $427.36 | 2024-2025 | Dextenza |
| Genentech, INC. | $349.47 | 2022-2024 | Enspryng, Vabysmo |
| Spark Therapeutics, INC. | $111.35 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $105.25 | 2021 | |
| Bausch & Lomb Americas INC. | $93.47 | 2022 | |
| Allergan, INC. | $90.43 | 2019 | |
| Horizon Therapeutics Plc | $84.32 | 2022 | |
| Eyepoint US, INC. | $82.39 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramanath Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.